LOM Asset Management Ltd Increases Position in Novo Nordisk A/S $NVO

LOM Asset Management Ltd increased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 1,448.4% in the third quarter, HoldingsChannel reports. The firm owned 16,490 shares of the company’s stock after buying an additional 15,425 shares during the period. LOM Asset Management Ltd’s holdings in Novo Nordisk A/S were worth $915,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in NVO. Martin Capital Partners LLC boosted its stake in Novo Nordisk A/S by 53.8% in the third quarter. Martin Capital Partners LLC now owns 117,577 shares of the company’s stock valued at $6,524,000 after acquiring an additional 41,129 shares in the last quarter. Smith Chas P & Associates PA Cpas increased its position in shares of Novo Nordisk A/S by 105.3% during the third quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company’s stock worth $22,497,000 after purchasing an additional 207,959 shares in the last quarter. Clifford Swan Investment Counsel LLC lifted its holdings in shares of Novo Nordisk A/S by 13.7% during the 3rd quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company’s stock valued at $17,267,000 after purchasing an additional 37,453 shares during the last quarter. Markel Group Inc. lifted its holdings in shares of Novo Nordisk A/S by 4.9% during the 3rd quarter. Markel Group Inc. now owns 2,368,649 shares of the company’s stock valued at $131,436,000 after purchasing an additional 110,061 shares during the last quarter. Finally, Cantor Fitzgerald Investment Advisors L.P. acquired a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth $1,294,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 1.4%

NYSE:NVO opened at $39.02 on Friday. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The company’s fifty day moving average price is $51.68 and its 200-day moving average price is $52.48. Novo Nordisk A/S has a 1-year low of $35.85 and a 1-year high of $89.03. The firm has a market capitalization of $174.22 billion, a P/E ratio of 11.24 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, beating the consensus estimate of $0.90 by $0.11. The company had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. As a group, equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Dividend Announcement

The business also recently declared a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be given a dividend of $1.2751 per share. This represents a yield of 541.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 52.74%.

Analyst Upgrades and Downgrades

A number of research firms have commented on NVO. CICC Research started coverage on Novo Nordisk A/S in a research note on Friday, January 9th. They issued an “outperform” rating and a $73.50 price target for the company. TD Cowen reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 3rd. BMO Capital Markets reiterated a “market perform” rating on shares of Novo Nordisk A/S in a research note on Thursday, February 5th. HSBC restated a “hold” rating and set a $54.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, December 10th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. Five equities research analysts have rated the stock with a Buy rating, seventeen have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $53.93.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Morgan Stanley raised NVO to Equal Weight, reducing downside concerns from that shop and providing some support for the shares. Novo Nordisk A/S (NYSE:NVO) Raised to Equal Weight at Morgan Stanley
• Positive Sentiment: Market reaction to the FDA’s tighter scrutiny of telehealth GLP‑1 advertisers lifted NVO as investors expect larger incumbent manufacturers to benefit if smaller/telehealth competitors face limits. Novo Nordisk (NVO) Stock Jumps 3% as FDA Cracks Down on Telehealth GLP-1 Advertisers
• Neutral Sentiment: Goldman Sachs reiterated a Neutral rating on NVO, leaving the firm’s guidance unchanged and offering little directional push. The Goldman Sachs Group Reaffirms “Neutral” Rating for Novo Nordisk A/S (NYSE:NVO)
• Neutral Sentiment: Market commentary is debating Novo Nordisk’s valuation after the recent share decline; some pieces argue pessimism may be overdone while others call for catalyst clarity — this keeps near-term sentiment mixed. Novo Nordisk (NYSE:NVO) Valuation Debate Lingers As Market Awaits Catalyst Clarity
• Neutral Sentiment: Analysis pieces are questioning whether the recent selloff has priced in too much pessimism, which can attract value‑oriented buyers if fundamentals hold. Is Novo Nordisk (NYSE:NVO) Now Pricing In Too Much Pessimism After Share Price Slump
• Negative Sentiment: FDA has issued another warning letter to Novo Nordisk over an “Only One Ozempic” ad and broader GLP‑1 advertising concerns — increased regulatory scrutiny of marketing claims raises compliance risk and potential reputational damage. Novo Nordisk slammed with another FDA letter for ‘Only One Ozempic’ ad
• Negative Sentiment: Additional reporting confirms the FDA’s second warning over GLP‑1 ads, reinforcing regulatory/headline risk that could pressure sentiment and invite closer agency oversight. FDA sends Novo Nordisk 2nd warning over GLP-1 ads
• Negative Sentiment: The American Hospital Association urged HRSA to block Novo Nordisk’s new claims-data submission policy for 340B hospitals, signaling potential pushback from hospital customers and possible distribution/contracting friction. AHA urges HRSA to stop Novo Nordisk’s new claims-data submission policy on 340B hospitals from going into effect
• Negative Sentiment: Pomerantz LLP announced an investor investigation into Novo Nordisk, which could foreshadow litigation or shareholder claims and add legal uncertainty. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S – NVO

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.